A Skolkovo resident raised RUB 155 million from business angels for the development of vaccines.
A biotech company of the Human Stem Cell Institute (HSCI), RBT, raised RUB 155 million during its private offering on the Rounds investment platform for Skolkovo residents.
RBT (BioTechnology Developments) planned to attract 50 to 160 million rubles. The offering was at the top of the price range, with oversubscription. The total of orders from investors wishing to take part in the company’s first investment round reached more than RUB 251 million.
As investors rushed to complete transactions and receive Skolkovo’s benefits, only a part of the orders were satisfied. 860 investors became the company’s shareholders. With the opportunity to receive a benefit from the Skolkovo Foundation (reimbursement of up to 50% of the investment amount), 59 people invested RUB 110 million in RBT.
Igor Krasilnikov, RBT’s director: “The offering was successful thanks to HSCI’s ecosystem and “Skolkovo”’s support for investors. This is a good example showing that Russian investors are interested in biotech. And biotech is able to attract investment in the venture capital market for its development. We plan to use the investments to expand RBT’s development portfolio.”
Vladimir Yegorov, Operations Director of the Skolkovo Foundation Biomedical Technologies Cluster: “HSCI is an official partner of the Skolkovo Foundation developing a number of promising projects in the field of high-tech medicine, such as gene therapy, cell technologies and vaccines, at the Innovation Center. Thanks to our cooperation, we can expand and improve support mechanisms for innovative companies. RBT’s offering was the first experience in raising funds using an investment platform with an option to receive compensation through our program later on. RBT already has a good portfolio of products at various stages of readiness, and their vaccine development platform has significant potential for its expansion.”